Focus Partners Advisor Solutions LLC Makes New Investment in Sanofi (NASDAQ:SNY)

Focus Partners Advisor Solutions LLC acquired a new position in shares of Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,414 shares of the company's stock, valued at approximately $502,000.

Several other large investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its position in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after acquiring an additional 5,091,304 shares during the period. Raymond James Financial Inc. acquired a new position in Sanofi in the fourth quarter valued at about $135,933,000. Boston Partners lifted its position in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC boosted its stake in Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after buying an additional 1,705,148 shares during the period. Finally, Point72 Asset Management L.P. increased its position in shares of Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after acquiring an additional 861,770 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY traded down $0.40 during trading on Wednesday, hitting $51.99. The stock had a trading volume of 3,469,024 shares, compared to its average volume of 2,383,350. The firm has a market capitalization of $131.34 billion, a P/E ratio of 20.88, a PEG ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company's 50-day moving average price is $52.54 and its 200 day moving average price is $51.90.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business's revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.78 earnings per share. On average, equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. Sanofi's payout ratio is presently 57.14%.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Three analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.